Advertisement
Screener

CEL-SCI CORPORATION (CVM) ROE

CEL SCI CORP ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • CEL SCI CORP roe for the quarter ending 2026-06-30 was -207.23%, a change of 154.62% year-over-year.
  • CEL SCI CORP roe for the quarter ending 2026-03-31 was -330.21%, a change of 2.52% year-over-year.
  • CEL SCI CORP roe for the quarter ending 2025-12-31 was -213.74%, a change of 27.53% year-over-year.
  • CEL SCI CORP roe for the quarter ending 2025-09-30 was -159.25%, a change of 49.97% year-over-year.
  • CEL SCI CORP roe for fiscal 2025 was -159.25%, a change of 49.97% from fiscal 2024.
  • CEL SCI CORP roe for fiscal 2024 was -209.22%, a change of 35.70% from fiscal 2023.
  • CEL SCI CORP roe for fiscal 2023 was -244.92%, a change of -130.81% from fiscal 2022.
  • CEL SCI CORP roe for fiscal 2022 was -114.11%, a change of -49.79% from fiscal 2021.
Available history
2009-09-30 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-207.23%-$22.7M-$5.67M$10.96M
2026-03-31-330.21%-$22.7M-$5.47M$6.87M
2025-12-31-213.74%-$23.81M-$5.47M$11.14M
2025-09-30-159.25%-$25.41M-$6.10M$15.96M
2025-06-30-361.85%-$25.42M-$5.66M$7.02M
2025-03-31-332.73%-$26.61M-$6.57M$8M
2024-12-31-241.27%-$27.28M-$7.07M$11.31M
2024-09-30-209.22%-$26.92M-$6.11M$12.87M
2024-06-30-337.70%-$28.61M-$6.86M$8.47M
2024-03-31-210.59%-$30.12M-$7.24M$14.3M
2023-12-31-246.81%-$31.22M-$6.71M$12.65M
2023-09-30-244.92%-$32.37M-$7.80M$13.21M
2023-06-30-223.31%-$33.03M-$8.37M$14.79M
2023-03-31-170.20%-$34.29M-$8.34M$20.15M
2022-12-31-134.52%-$35.77M-$7.85M$26.59M
2022-09-30-114.11%-$36.7M-$8.46M$32.16M
2022-06-30-94.10%-$36.44M-$9.63M$38.73M
2022-03-31-79.22%-$35.75M-$9.82M$45.13M
2021-12-31-72.46%-$37.21M-$8.78M$51.35M
2021-09-30-64.32%-$36.36M-$8.20M$56.53M
2021-06-30-56.09%-$33.54M-$8.94M$59.79M
2021-03-31-118.90%-$34.87M-$11.28M$29.33M
2020-12-31-113.27%-$32.66M-$7.94M$28.84M
2020-09-30-153.37%-$30.26M-$5.38M$19.73M
2020-06-30-142.30%-$29.72M-$10.28M$20.89M
2020-03-31-223.03%-$31.53M-$9.07M$14.14M
2019-12-31-322.89%-$28.91M-$5.53M$8.95M
2019-09-30-431.17%-$22.13M-$4.85M$5.13M
2019-06-30-2810.18%-$32.21M-$12.08M$1.15M
2019-03-31-2735.99%-$26.14M-$6.45M$955,522.00
2018-12-31-901.21%-$24.4M$1.25M$2.71M
2018-09-30-3475677.40%-$31.84M-$14.93M$916.00
2018-06-301749.93%-$21.9M-$6.01M-$1.25M
2018-03-31665.54%-$20.35M-$4.71M-$3.06M
2017-12-31497.97%-$24.07M-$6.19M-$4.83M
2017-09-30430.43%-$14.36M-$4.99M-$3.34M
2017-06-30206.50%-$10.5M-$4.46M-$5.08M
2017-03-31349.40%-$9.9M-$8.43M-$2.83M
2016-12-31-219.92%-$10.32M$3.52M$4.69M
2016-09-301694.98%-$11.51M-$1.13M-$679,213.00
2016-06-30536.48%-$20.25M-$3.86M-$3.77M
2016-03-31708.29%-$20.81M-$8.86M-$2.94M
2015-12-31-694.11%-$24.51M$2.33M$3.53M
2015-09-30728.48%-$34.69M-$9.86M-$4.76M
2015-06-30-815.94%-$32.04M-$4.43M$3.93M
2015-03-31-8760.74%-$30.05M-$12.56M$343,056.00
2014-12-31-260.70%-$30.86M-$7.85M$11.84M
2014-09-30-253.65%-$27.35M-$7.22M$10.78M
2014-06-30-145.27%-$21.84M-$2.44M$15.04M
2014-03-31-324.18%-$23.85M-$13.37M$7.36M
2013-12-31-74.08%-$11.2M-$4.33M$15.11M
2013-09-30-136.88%-$9.17M-$1.70M$6.7M
2013-06-30-128.71%-$10.04M-$4.45M$7.8M
2013-03-31-55.65%-$6.43M-$713.37K$11.55M
2012-12-31-122.24%-$14.21M-$2.31M$11.62M
2012-09-30-220.24%-$15.48M-$2.57M$7.03M
2012-06-30-168.94%-$15.23M-$835.45K$9.01M
2012-03-31-280.49%-$17.51M-$8.49M$6.24M
2011-12-31-284.04%-$23.04M-$3.58M$8.11M
2011-09-30-283.21%-$25.71M-$2.32M$9.08M
2011-06-30-334.56%-$30.73M-$3.11M$9.18M

Annual ROE

DateROENet income 12 monthShareholder equity
2025-09-30-159.25%-$25.41M$15.96M
2024-09-30-209.22%-$26.92M$12.87M
2023-09-30-244.92%-$32.37M$13.21M
2022-09-30-114.11%-$36.7M$32.16M
2021-09-30-64.32%-$36.36M$56.53M
2020-09-30-153.37%-$30.26M$19.73M
2019-09-30-431.17%-$22.13M$5.13M
2018-09-30-3475677.40%-$31.84M$916.00
2017-09-30430.43%-$14.36M-$3.34M
2016-09-301694.98%-$11.51M-$679,213.00
2015-09-30728.48%-$34.69M-$4.76M
2014-09-30-253.65%-$27.35M$10.78M
2013-09-30-136.88%-$9.17M$6.7M
2012-09-30-220.24%-$15.48M$7.03M
2011-09-30-283.21%-$25.71M$9.08M
2010-09-3037.64%$10.48M$27.85M
2009-09-30-462.75%-$40.91M$8.84M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quince Therapeutics, Inc. (QNCX)United States$0.031B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Scilex Holding Co (SCLX)United States$0.042B-0.14
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
LeonaBio, Inc. (LONA)United States$0.047B-0.61